InflaRx NV (IFRX)
NASDAQ:IFRX
Want to see IFRX full AI Analyst Report?
Top Page
InflaRx
(NASDAQ:IFRX)
Select Model
Select Model
Rating:50Neutral
Price Target:
$2.00
▲(25.79% Upside)
Action:ReiteratedDate:04/30/26
The score is held back primarily by very weak financial performance (minimal/declining revenue, persistent losses, and ongoing cash burn), partially offset by a relatively low-debt balance sheet. Technicals are supportive due to strong upward momentum, but overbought signals add near-term risk, while valuation is difficult to support given negative earnings and no dividend data.
Positive Factors
Low debt / conservative balance sheet
Very low reported debt reduces refinancing and interest-rate risks, preserving strategic optionality for a clinical-stage biotech. This balance-sheet conservatism supports the company’s ability to fund development, pursue partnerships, or weather trial timelines without near-term solvency pressure.
Negative Factors
Minimal and declining revenue
Sharp, persistent revenue declines indicate the company remains far from a recurring commercial model. For a clinical-stage biotech without marketed products, falling revenue heightens reliance on financing events or partnerships, which can dilute shareholders and constrain long-term investment flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Low debt / conservative balance sheet
Very low reported debt reduces refinancing and interest-rate risks, preserving strategic optionality for a clinical-stage biotech. This balance-sheet conservatism supports the company’s ability to fund development, pursue partnerships, or weather trial timelines without near-term solvency pressure.
Read all positive factors
InflaRx (IFRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$151.82M
Dividend YieldN/A
Average Volume (3M)739.26K
Price to Earnings (P/E)―
Beta (1Y)1.53
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees74
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.66
Shares Outstanding72,292,860
10 Day Avg. Volume1,547,389
30 Day Avg. Volume739,257
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)1.39
Price to Sales (P/S)2053.09
P/FCF Ratio-1.70
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue4.14K
Enterprise Value/Gross Profit-15.86
Enterprise Value/Ebitda-2.41
Forecast
1Y Price Target
$8.33Price Target Upside424.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.61
Revenue Forecast (FY)$13.83K
InflaRx Business Overview & Revenue Model
Company Description
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a var...
How the Company Makes Money
InflaRx is a clinical-stage company and, based on publicly available information, it has not established a broad, recurring revenue base from marketed products. Its potential and/or historical sources of cash and revenue typically include: (1) col...
InflaRx Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
54
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.17K | 165.79K | 63.09K | 0.00 | 0.00 |
| Gross Profit | -7.36M | -3.15M | -469.17K | -627.01K | -791.26K |
| EBITDA | -48.50M | -45.55M | -42.06M | -30.31M | -53.11M |
| Net Income | -43.83M | -46.06M | -42.67M | -30.99M | -53.93M |
Balance Sheet | |||||
| Total Assets | 55.19M | 76.02M | 120.21M | 102.40M | 125.14M |
| Cash, Cash Equivalents and Short-Term Investments | 46.44M | 18.38M | 12.77M | 81.81M | 83.41M |
| Total Debt | 897.53K | 805.09K | 1.12M | 1.36M | 1.43M |
| Total Liabilities | 13.65M | 14.60M | 17.63M | 14.05M | 19.86M |
| Stockholders Equity | 41.54M | 61.42M | 102.58M | 88.35M | 105.28M |
Cash Flow | |||||
| Free Cash Flow | -34.03M | -48.60M | -37.89M | -33.91M | -39.97M |
| Operating Cash Flow | -33.92M | -48.56M | -37.81M | -33.74M | -39.94M |
| Investing Cash Flow | 3.11M | 52.36M | -17.70M | 19.36M | -25.95M |
| Financing Cash Flow | 32.00M | 386.45K | 52.99M | 1.94M | 61.58M |
InflaRx Technical Analysis
Positive
1.59
Price Trends
0.95
Positive
1.00
Positive
1.09
Positive
Market Momentum
0.10
Negative
83.42
Negative
88.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IFRX, the sentiment is Positive. The current price of 1.59 is above the 20-day moving average (MA) of 1.02, above the 50-day MA of 0.95, and above the 200-day MA of 1.09, indicating a bullish trend. The MACD of 0.10 indicates Negative momentum. The RSI at 83.42 is Negative, neither overbought nor oversold. The STOCH value of 88.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IFRX.
InflaRx Risk Analysis
InflaRx disclosed 82 risk factors in its most recent earnings report. InflaRx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
InflaRx Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $160.98M | 1.39 | 43.14% | ― | ― | ― | |
52 Neutral | $72.32M | -2.21 | 240.83% | ― | -41.52% | 42.50% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $151.82M | -1.32 | -81.77% | ― | ― | ― | |
42 Neutral | $41.71M | -16.66 | -79.12% | ― | -6.33% | ― | |
| ― | $105.28M | -9.85 | -65.55% | ― | ― | 19.02% | |
45 Neutral | $171.90M | -1.27 | -111.27% | ― | ― | -17.56% |
* Healthcare Sector Average
IFRX
InflaRx
2.13
0.48
29.09%
ORMP
Oramed Pharm
3.93
1.78
82.54%
ATRA
Atara Biotherapeutics
4.88
-2.37
-32.69%
ANIX
Anixa Biosciences
3.06
0.25
8.90%
CLNN
Clene
8.09
5.18
178.01%
ABOS
Acumen Pharmaceuticals
2.48
1.44
138.46%
InflaRx Corporate Events
InflaRx Regains Nasdaq Minimum Bid Price Compliance, Securing Listing Status
Apr 28, 2026
InflaRx N.V., a Nasdaq-listed biopharmaceutical group based in Germany and the U.S., focuses on anti-inflammatory drugs that inhibit the complement activation factor C5a and its receptor, C5aR. Its lead candidate is izicopan, an oral C5a receptor ...
InflaRx Shareholders Approve Capital, Governance Changes and 2026 Incentive Plan at April AGM
Apr 23, 2026
On April 23, 2026, InflaRx held its annual general meeting of shareholders, where investors approved the Dutch statutory annual accounts for the year ended December 31, 2025, and reappointed KPMG Accountants N.V. as external auditor for 2026. Shar...
InflaRx Highlights New Izicopan Data Showing No CYP3A4 Time-Dependent Inhibition
Apr 9, 2026
On April 9, 2026, InflaRx reported new in vitro mechanistic data showing that its lead candidate izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme involved in metabolizing many drugs and a common source of drug–drug...
InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP
Apr 2, 2026
On April 2, 2026, InflaRx N.V. announced it had convened its 2026 annual general meeting of shareholders for April 23, 2026 in Amsterdam, setting March 26, 2026 as the record date and outlining attendance and proxy procedures for registered and be...
InflaRx Shifts Strategy to Izicopan as 2025 Results Extend Cash Runway to 2027
Mar 19, 2026
On March 19, 2026, InflaRx reported its full-year 2025 results and outlined a strategic pivot to focus on izicopan after promising Phase 2a data in hidradenitis suppurativa and chronic spontaneous urticaria, with Phase 2b planning in HS underway a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.